ArticleInorganic chemistry2020
Polyazamacrocycle Ligands Facilitate
Article in Inorganic chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Design Strategies for Developing Chiral Macrocyclic Chelators as a Diagnostic Tool.Accounts of chemical research · 2026Article
- Stable Chelation of Zr-89 and Ac-225 with Dual Size-Selective Macrocyclic pyInorganic chemistry · 2026Article
- Synthesis and Evaluation of D8W, an Octadentate Desferrioxamine Analogue with Enhanced Water Solubility Designed forMolecular pharmaceutics · 2026Article
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- The Evaluation of (1Molecules (Basel, Switzerland) · 2025Article
- Speciation and Complex Formation of Zirconium(IV) with Tc(VII) and Re(VII) in Liquid-Liquid Extraction Systems.ACS omega · 2025Article
- Protein-based Radiopharmaceuticals that target fibroblast activation protein alpha: a review of current progress.EJNMMI radiopharmacy and chemistry · 2025Review
- A first-in-class dual-chelator theranostic agent designed for use with imaging-therapy radiometal pairs of different elements.Chemical science · 2024Article
- Zirconium 89 and Copper 64 for ImmunoPET: From Antibody Bioconjugation and Radiolabeling to Molecular Imaging.Pharmaceutics · 2024Review
- Bifunctional octadentate pseudopeptides as Zirconium-89 chelators for immuno-PET applications.EJNMMI radiopharmacy and chemistry · 2024Article
- Self-Illuminating In Situ Hydrogel with Immune-Adjuvant Amplify Cerenkov Radiation-Induced Photodynamic Therapy.Chemical & biomedical imaging · 2024Article
- Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7.Molecules (Basel, Switzerland) · 2024Review
- Investigation of Two Zr-p-NOEuropean journal of inorganic chemistry · 2023Article
- Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, andACS omega · 2022Article
- Evaluation of differentScientific reports · 2022Article
- The Race for Hydroxamate-Based Zirconium-89 Chelators.Cancers · 2021Review
- State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET.Bioconjugate chemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
Abstract
Over the last three decades, the chemistry of zirconium has facilitated antibody development and the clinical management of disease in the precision medicine era. Scientists have harnessed its reactivity, coordination chemistry, and nuclear chemistry to develop antibody-based radiopharmaceuticals incorporating zirconium-89 (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.